Nilotinib has been tested for the potential treatment of epileptic seizures [194], tauopathies [40,41,195], alpha-synucleinopathies [40,42,196,197,198], TDP-43 pathology [64,65], beta-amyloid pathology [195], AD [60,199,200,201], Parkinson’s disease [202,203,204], chorea-acanthocytosis [205,206], and Niemann–Pick type A disease [184]. The gene discussed is TARDBP; the disease is Parkinson disease.